AN
ANEB.US Anebulo Pharmaceuticals Inc
- Market cap
- USD 11.4M
- P/E
- -
- P/B
- 0.01x
- ROE
- -104.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Dec 2025.
Is ANEB.US undervalued?
Graham numberThe Graham number of Anebulo Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anebulo Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Anebulo Pharmaceuticals Inc yet.
Anebulo Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicit…
Full company profileAnebulo Pharmaceuticals Inc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anebulo Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -173K | -3.61M | -6.83M | -11.8M | -8.31M | -9.22M | -9.76M |
| EBITDA | -173K | -30.2M | -6.83M | -11.8M | -7.90M | -7.72M | -8.21M |
| Net Income | -175K | -30.3M | -6.83M | -11.7M | -8.20M | -8.48M | -8.32M |
| EPS | -0.01 | -1.30 | -0.29 | -0.47 | -0.32 | -0.25 | -0.20 |
| Balance Sheet | |||||||
| Total Assets | 3.03M | 21.7M | 15.6M | 11.7M | 4.07M | 12.1M | 9.42M |
| Total Liabilities | 224K | 242K | 513K | 1.07M | 261K | 488K | 1.49M |
| Shareholders' Equity | 2.80M | 21.4M | 15.1M | 10.6M | 3.81M | 11.7M | 7.94M |
| Cash & Short-term Investments | 3.02M | 20.0M | 14.5M | 11.2M | 3.09M | 11.6M | 9.04M |
| Total Debt | 201K | - | - | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -151K | -4.87M | -5.44M | -9.68M | -8.09M | -6.35M | -5.17M |
| Capital Expenditure | 2.00 | 0.00 | 4.00 | 0.00 | 1.00 | 3.00 | 0.00 |
| Free Cash Flow | -151K | -4.87M | -5.44M | -9.68M | -8.09M | -6.35M | -5.17M |
| Ratios | |||||||
| ROE | -6.2% | -141.3% | -45.3% | -110.7% | -215.1% | -72.8% | -104.8% |
| ROA | -5.8% | -139.7% | -43.8% | -100.5% | -201.4% | -69.9% | -88.3% |
| Debt to Equity | 0.07x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anebulo Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 8.21M | 0.35 | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Anebulo Pharmaceuticals Inc
- Insiders 40.84%
- Institutions 0.00%
- Public & others 59.17%
- Shares outstanding 40.8M
- Free float 24.1M
Top funds holding ANEB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Total Market Index Strategy | 82.00 | 0.00% | -2.38% | Sep 2025 |
Top institutions holding ANEB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| 22NW, LP | 0.00 | 0.00% | -100.00% | Mar 2026 |
| State Street Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Ikarian Capital, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Mangrove Partners | 0.00 | 0.00% | -100.00% | Mar 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Nantahala Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
Anebulo Pharmaceuticals Inc company profile
- Company name
- Anebulo Pharmaceuticals Inc
- Ticker
- ANEB.US
- Exchange
- USA Stocks
- Listed since
- May 7, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- June
- Address
- 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734
- Phone
- 512 598 0931
- Website
- anebulo.com
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Anebulo Pharmaceuticals Inc management
4- Dr. Joseph F. Lawler M.D., Ph.D.Founder & Chairman · born 1972
- Mr. Richard Anthony CunninghamCEO & Director · born 1971
- Mr. Daniel V. GeorgeActing CFO & Secretary · born 1970
- Dr. Kenneth C. Cundy Ph.D.Chief Scientific Officer · born 1959